1
|
Ballard A, Thamm C, Ogle T, Phillips JL. Influences Shaping Clinicians' Monoclonal Antibody and Immune Checkpoint Inhibitor Preparation and Administration Management Practices: A Systematic Review. Semin Oncol Nurs 2024; 40:151583. [PMID: 38336551 DOI: 10.1016/j.soncn.2024.151583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2023] [Revised: 12/16/2023] [Accepted: 01/09/2024] [Indexed: 02/12/2024]
Abstract
OBJECTIVES In 30 years, monoclonal antibodies (mAbs) and immune checkpoint inhibitors (ICPIs) have enhanced cancer survival and quality of life. Limited knowledge exists regarding the long-term risks of repeated exposure, especially for cancer nurses, who prepare and administer them. This systematic review aimed to identify influences shaping clinicians' awareness and practices in the safe preparation and administration of mAbs and ICPIs. DATA SOURCES This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The databases CINAHL, EMBASE, Joanna Briggs Institute, OVID, MEDLINE, and Cochrane were searched. Eligibility and risk of bias were assessed by four reviewers. RESULTS Of 7301 identified studies, 481 duplicates were removed, and 6673 were excluded after title and abstract review. A full-text review was conducted on 147 studies; six studies were included. A narrative synthesis generated two themes: (1) ambiguity contributes to variation in handling practices and (2) continuing professional development (CPD) is vital but hard to implement without evidence. CONCLUSION Lack of evidence regarding long-term risks and consensus creates uncertainty about the hazardous nature of unconjugated mAbs and ICPIs. Resulting in varied risk reduction strategies during preparation and administration, and inconsistent CPD. Protecting the long-term health of clinicians necessitates consensus on risk reduction strategies. This will be challenging without compelling evidence or international agreement on their hazardous classification. IMPLICATIONS FOR NURSING PRACTICE In nursing, policy gaps and inconsistent CPD related to unconjugated mAbs and ICPIs may expose nurses to risks. Understanding the educational needs of nurses and global standardized guidelines are urgently needed.
Collapse
Affiliation(s)
- Angela Ballard
- Ph.D Candidate, School of Nursing, Queensland University of Technology (QUT), Brisbane, Queensland; Lecturer, Federation University, Institue of Health and Wellbeing, Berwick, Victoria, Australia.
| | - Carla Thamm
- Senior Research Fellow, Caring Futures Institute, School of Nursing and Health Sciences, Flinders University, Adelaide, South Australia; Senior Lecturer, School of Nursing, Queensland University of Technology (QUT), Brisbane, Australia
| | - Theodora Ogle
- Lecturer, School of Nursing, Queensland University of Technology (QUT) Brisbane, Queensland, Australia
| | - Jane L Phillips
- Professor, Head of School, School of Nursing, Queensland University of Technology (QUT), Brisbane, Queensland, Australia
| |
Collapse
|
2
|
Videira NB, Nair V, Paquet V, Calhoun D. The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits. J Appl Toxicol 2024; 44:216-234. [PMID: 37646119 DOI: 10.1002/jat.4533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2023] [Revised: 07/25/2023] [Accepted: 08/11/2023] [Indexed: 09/01/2023]
Abstract
Serotonergic psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), are currently being investigated for the treatment of psychiatric disorders such as depression and anxiety. Clinical trials with psilocybin and LSD have shown improvement in emotional and psychological scores. Although these drugs are reported to be safe in a controlled environment (such as clinical trials), exposure to low doses of these drugs can result in psychedelic effects, and therefore, occupational safety is an important consideration to prevent adverse effects in the workplace from low daily exposure. This article will discuss the factors involved in the derivation of occupational exposure limits (OELs) and risk assessment of these psychedelic drugs. To support the OEL derivations of psychedelic drugs, information regarding their mechanism of action, adverse effect profiles, pharmacokinetics, clinical effects, and nonclinical toxicity were considered. Additionally, psilocybin and LSD, which are the most extensively researched psychedelic substances, are employed as illustrative examples in case studies. The OELs derived for psilocybin and for LSD are 0.05 and 0.002 μg/m3 , respectively, which indicates that these are highly hazardous compounds, and it is important to take into account suitable safety measures and risk-management strategies in order to minimize workplace exposure.
Collapse
Affiliation(s)
| | | | - Valérie Paquet
- formerly Affygility Solutions, Broomfield, Colorado, USA
| | | |
Collapse
|
3
|
Ryan M, Lam N, Wright K, Siderov J. Clinical Oncology Society of Australia Position Statement: 2022 update to the safe handling of monoclonal antibodies in healthcare settings. Asia Pac J Clin Oncol 2023; 19:723-730. [PMID: 36899469 DOI: 10.1111/ajco.13943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Revised: 01/13/2023] [Accepted: 01/17/2023] [Indexed: 03/12/2023]
Abstract
AIM The aims were to (a) review the scientific literature on occupational risk, including exposure mechanisms and risk assessment, with regards to handling monoclonal antibodies (mABs) in healthcare settings; and (b) update the recommendations in the Clinical Oncology Society of Australia (COSA) safe handling of monoclonal antibodies in healthcare settings position statement, published in 2013. METHODS A literature search was conducted between April 24, 2022, and July 3, 2022, to identify evidence relating to occupational exposure and handling of mABs in healthcare settings. Evidence in the literature was compared to the Position Statement published in 2013, and any potential additions, deletions, or revisions were discussed by the authors, and then agreed changes were made. RESULTS Thirty-nine references were included in this update, comprising of the 2013 Position Statement itself and 10 of its references, as well as 28 new references. The risks to healthcare workers in the preparation and administration of mABs arise from four distinct exposure mechanisms: dermal, mucosal, inhalation, and oral. Updates included recommendations on using protective eyewear during the preparation and administration of mABs, developing a local institutional risk assessment tool and handling recommendations, considerations for using closed system transfer devices, and to have awareness of the nomenclature change from 2021 for new mABs. CONCLUSION Practitioners should follow the 14 recommendations to lower occupational risk when handling mABs. Another Position Statement update should occur in 5-10 years to ensure the currency of recommendations.
Collapse
Affiliation(s)
- Marissa Ryan
- Department of Pharmacy, Princess Alexandra Hospital, Brisbane, Australia
- Centre for Health Services Research, The University of Queensland, Brisbane, Australia
- Centre for Online Health, The University of Queensland, Brisbane, Australia
| | - Neil Lam
- Icon Cancer Centre River City Pharmacy, Brisbane, Australia
| | - Kate Wright
- Central West Cancer Care Centre, Orange, Australia
- Department of Pharmacy, Orange Health Service, Orange, Australia
| | - Jim Siderov
- Department of Pharmacy, Austin Health, Melbourne, Australia
| |
Collapse
|
4
|
Bacauanu V, Merz ZN, Hua ZL, Lang SB. Nickel-Catalyzed Antibody Bioconjugation. J Am Chem Soc 2023; 145:25842-25849. [PMID: 37950853 DOI: 10.1021/jacs.3c10185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2023]
Abstract
New biocompatible methods for post-translational protein modification are challenging to develop but crucial to create improved chemical probes and optimize next-generation biologic therapies such as antibody-drug conjugates (ADCs). Herein, we describe the bottom-up construction of an aqueous nickel-catalyzed cross-coupling for the chemospecific arylation of cysteine residues on peptides and proteins and its use for the preparation of ADCs. A variety of arene linkages are exemplified, enabling the incorporation of small molecules, probes, and cytotoxic payloads. The utility of this new bioconjugation platform in a drug discovery setting is highlighted by the construction of novel ADCs with target-mediated in vitro cytotoxic activity.
Collapse
Affiliation(s)
- Vlad Bacauanu
- Discovery Chemistry, Merck & Co., Inc., South San Francisco, California 94080, United States
| | - Zoe N Merz
- Discovery Chemistry, Merck & Co., Inc., South San Francisco, California 94080, United States
| | - Zhong L Hua
- Discovery Oncology, Merck & Co., Inc., South San Francisco, California 94080, United States
| | - Simon B Lang
- Discovery Chemistry, Merck & Co., Inc., South San Francisco, California 94080, United States
| |
Collapse
|
5
|
Wu Q, Elkind S, Preston F, Wachala M, Dunn E, White SK, Windhorst D, DiGiandomenico K, McGuire C, Brok H, Hodges R. An Industry Proposal for a Cell and Gene Therapy Safety Data Sheet. APPLIED BIOSAFETY 2023; 28:176-191. [PMID: 37736420 PMCID: PMC10510680 DOI: 10.1089/apb.2023.0009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/23/2023]
Abstract
Introduction A safety data sheet (SDS) is an established hazard communication tool for chemicals, for which no comparable document exists in the biotherapeutics industry. As the cell and gene therapy (CGT) field expands, industry leaders have identified a growing need to address this gap in communication of the unique occupational health and safety risks posed by CGT materials and products. Methods Following the sections of a traditional chemical SDS, information was modified by industry subject matter experts, relevant to CGT biological materials. This guide was developed based on assumptions of a maximum biosafety level 2, and any chemical components present in the material were excluded from the hazard classification. Results The guide contains necessary information to conduct a workplace risk assessment and communicate the unique workplace hazards posed by potential exposures to the material. The target audience is intended to be entities handling and producing these materials, plus collaborators, contractors, or operations sites receiving and handling the CGT material. An example of a CGT SDS is provided in Table 1. Discussion The CGT SDS provides industry with a best practice to address an existing gap in hazard communication for CGT. We expect that, as the field evolves, so may the contents. The CGT SDS can be used as a reference for other biological modalities in the field. Conclusions This initial CGT SDS communicates workplace hazards and assesses the unique risks posed by these biological materials and can assist in creating exposure control plans specific to the workplace hazards.
Collapse
Affiliation(s)
- Qirong Wu
- Janssen, Spring House, Pennsylvania, USA
| | - Shana Elkind
- Rocket Pharmaceuticals, Inc., Cranbury, New Jersey, USA
| | - Francine Preston
- Johnson & Johnson Services, Inc., Spring House, Pennsylvania, USA
| | | | - Erin Dunn
- Fujifilm Diosynth Biotechnologies, College Station, Texas, USA
| | | | | | | | - Colin McGuire
- Formally of Thermo Fisher Scientific, Waltham, Massachusetts, USA
| | | | - Rachel Hodges
- BioPhorum Operations Group Ltd., London, United Kingdom
| |
Collapse
|
6
|
Wiesner L, Araya S, Lovsin Barle E. Identifying non-hazardous substances in pharmaceutical manufacturing and setting default Health-Based Exposure Limits (HBELs). J Appl Toxicol 2022; 42:1443-1457. [PMID: 35315528 DOI: 10.1002/jat.4323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 03/02/2022] [Accepted: 03/16/2022] [Indexed: 11/07/2022]
Abstract
Contract Development and Manufacturing Organizations (CDMOs) that manufacture large, diverse portfolio of chemical and pharmaceutical substances require pragmatic risk-based decisions with respect to the safe carry-over between different chemical entities, as well as for worker protection. Additionally, CDMOs may not have access to primary study data or data is generally lacking for a specific substance. While pharmaceuticals require the establishment of health-based exposure limits (HBELs) (e.g., occupational exposure limits, permitted daily exposure limits), the limits for non-hazardous substances could be set in a protective and pragmatic way by using default values, when internally required. Since there is no aligned definition provided by authorities, nor agreed default values for non-hazardous substances, we provide a decision tree in order to help qualified experts (such as qualified toxicologists) to identify the group of non-hazardous substances and to assign default HBEL values for specific routes of exposure. The non-hazardous substances discussed within this publication are part of the following subgroups: (I) inactive pharmaceutical ingredients, (II) pharmaceutical excipients or cosmetic ingredients, (III) substances Generally Recognized as Safe (GRAS), and (IV) food ingredients, additives and contact materials. The proposed default limit values are 1 mg/m3 for the OEL, and 50 mg/day for the PDE oral and IV (intravenous) route.
Collapse
|
7
|
Graham J, Yao H, Franklin E. Occupational Exposure Risks When Working with Protein Therapeutics and the Development of a Biologics Banding System. APPLIED BIOSAFETY 2021; 26:193-204. [DOI: 10.1089/apb.2021.0004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
| | - Hugh Yao
- Bristol Myers Squibb, New Brunswick, New Jersey, USA
| | | |
Collapse
|
8
|
Oliveira Neto GCD, Tucci HNP, Godinho Filho M, Lucato WC, Correia JMF. Performance evaluation of occupational health and safety in relation to the COVID-19 fighting practices established by WHO: Survey in multinational industries. SAFETY SCIENCE 2021; 141:105331. [PMID: 36569417 PMCID: PMC9761547 DOI: 10.1016/j.ssci.2021.105331] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Accepted: 04/29/2021] [Indexed: 05/07/2023]
Abstract
The coronavirus pandemic meant that companies had to adapt quickly to survive the challenging scenario and avoid losing market share or even going bankrupt. In this sense, employees dedicated to Occupational Health and Safety (OH&S) activities within organizations played a key role in ensuring that the recommendations of the World Health Organization (WHO) were properly implemented. Even so, no studies were identified in the literature that investigated how the practices to combat COVID-19 improved the performance related to employee safety and occupational health. This is what motivates the accomplishment of this work; evaluate how these practices improve safety and health-related performance. For this, a survey of multinational companies was carried out and, together with this research, a model for structural equations was developed. In the end, a correlation test was performed. The main results showed that practices to combat COVID-19, such as the provision of sanitizers, the adoption of social distance, the creation of new work shifts, and the disinfection of workplaces were related to improvements in safety and health performance through the implementation of a risk management and biological risk mitigation program. Meanwhile, the provision of emergency assistance has found stronger relationships with managerial and strategic actions.
Collapse
Affiliation(s)
- Geraldo Cardoso de Oliveira Neto
- Industrial Engineering Post-Graduation Program, Universidade Nove de Julho (UNINOVE), Vergueiro Street, 235/249 - 12 Floor, zip code: 01504-001, Liberdade, Sao Paulo, Brazil
| | - Henrricco Nieves Pujol Tucci
- Industrial Engineering Post-Graduation Program, Universidade Nove de Julho (UNINOVE), Vergueiro Street, 235/249 - 12 Floor, zip code: 01504-001, Liberdade, Sao Paulo, Brazil
| | - Moacir Godinho Filho
- Production Engineering Program, Federal University of São Carlos. Production Engineering Program, Federal University of São Carlos, Via Washington Luis, Km 235 - Monjolinho, zip code: 13565-905, Sao Paulo, Brazil
| | - Wagner Cezar Lucato
- Industrial Engineering Post-Graduation Program, Universidade Nove de Julho (UNINOVE), Vergueiro Street, 235/249 - 12 Floor, zip code: 01504-001, Liberdade, Sao Paulo, Brazil
| | - José Manuel Ferreira Correia
- Industrial Engineering Post-Graduation Program, Universidade Nove de Julho (UNINOVE), Vergueiro Street, 235/249 - 12 Floor, zip code: 01504-001, Liberdade, Sao Paulo, Brazil
| |
Collapse
|
9
|
Ahuja V, Krishnappa M. Approaches for setting occupational exposure limits in the pharmaceutical industry. J Appl Toxicol 2021; 42:154-167. [PMID: 34254327 DOI: 10.1002/jat.4218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Revised: 06/26/2021] [Accepted: 06/26/2021] [Indexed: 11/09/2022]
Abstract
The use of pharmaceutical drugs has provided a cure for many diseases. However, unintended exposure to drugs in the manufacturing workplace can cause significant health hazards to workers. It is important to protect the workforce from these deleterious effects by limiting exposure to an acceptable level, the occupational exposure limit (OEL). OEL is defined as airborne concentrations (expressed as a time-weighted average for a conventional 8-h workday and a 40-h work week) of a substance to which nearly all workers may be repeatedly exposed (for a working lifetime) without adverse effects. Determination of OELs has become very challenging over time, requiring an overall assessment of the preclinical and clinical data of the drug being manufactured. Previously, to derive OEL values, toxicologists used animal no-observed-adverse-effect level (NOAEL) data, which have been replaced with the overall assessment of animal and human data, placing a higher emphasis on human health-based data. A major advantage of working with human pharmaceuticals is that sufficient clinical data are available for them in most cases. The present manuscript reviews the latest knowledge regarding the derivation of occupational exposure limits as health-based exposure limits (HBELs) for pharmaceuticals. We have provided examples of OEL calculations for various drugs including levofloxacin (CAS No. 100986-85-4), dienogest (CAS no. 65928-58-7), and acetylsalicylic acid (ASA, CAS no. 50-78-2) using human data. This report will benefit professionals in the OEL domain in understanding this highly important, growing, and challenging field.
Collapse
Affiliation(s)
- Varun Ahuja
- Safety Assessment Department, Syngene International Limited, Bangalore, India
| | - Mohan Krishnappa
- Safety Assessment Department, Syngene International Limited, Bangalore, India
| |
Collapse
|
10
|
Active pharmaceutical contaminants in dietary supplements: A tier-based risk assessment approach. Regul Toxicol Pharmacol 2021; 123:104955. [PMID: 34022259 DOI: 10.1016/j.yrtph.2021.104955] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2021] [Revised: 04/10/2021] [Accepted: 05/06/2021] [Indexed: 11/23/2022]
Abstract
The presence of active pharmaceutical ingredients (APIs) in adulterated or contaminated dietary supplements is a current product safety concern. Since there are limited guidelines, and no published consensus methods, we developed a tier-based framework incorporating typical lines of evidence for determining the human health risk associated with APIs in dietary supplements. Specifically, the tiered approach outlines hazard identification and decision to test for APIs in products based on criteria for likelihood of contamination or adulteration, and evaluation of manufacturer production standards. For products with detectable levels of APIs, a variety of default approaches, including the use of fraction of the therapeutic dose and the threshold of toxicological concern (TTC), as well as health-based exposure limits (HBELs) are applied. In order to demonstrate its practical use, as well as any limitations and/or special considerations, this framework was applied to five dietary supplements (currently available to the public). We found that the detected levels of APIs in some dietary supplements were above the recommended dose of the drugs, and thus, pose a significant health risk to consumers and potentially workers involved in manufacturing of these supplements. The results support the value of increased product quality surveillance and perhaps regulatory activity.
Collapse
|